Canada, Novartis Issue Warning On Blood Pressure Drugs

Law360, New York (January 24, 2012, 8:26 PM EST) -- Canada’s health regulator and Novartis Pharmaceuticals Canada Inc. warned consumers Monday that blood pressure drugs Rasilez and Rasilez HCT could increase the risk of strokes and other health problems in patients with Type 2 diabetes.

In a jointly issued advisory, Health Canada and Novartis told consumers with Type 2 diabetes not to take the drugs with angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

Others with Type 2 diabetes not taking ACE or ARB drugs should consult their physicians to see if treatment with Rasilez or...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.